University of Rochester Initiates Phase 2 Clinical Trial Of Insmed Incorporated’s iPlex For The Treatment Of Myotonic Muscular Dystrophy; Trial Funded By National Institutes of Health (NIH) And MDA Grants

RICHMOND, Va. & ROCHESTER, N.Y. & TUCSON, Ariz.--(BUSINESS WIRE)--Jan. 4, 2006---- Insmed Incorporated (NASDAQ: INSM), a Richmond, Va., biotechnology company, the University of Rochester School of Medicine, and the Muscular Dystrophy Association (MDA) announced today the initiation of a Phase 2 clinical study investigating the use of iPlex(TM) (mecasermin rinfabate (rDNA origin) injection), a once-daily IGF-1 therapy, for the treatment of myotonic muscular dystrophy (MMD), the most common form of adult muscular dystrophy.